January 13, 2005 -- After trading in a narrow range for most of the day, biotech sank during the last 1 1/2 hours, with the Centient Biotech 200 losing 1.39% or 47.11 points to close at 3337.57. Despite the overall gloom and doom, individual biotech companies managed to buck the trend and move up, based on positive news. We discuss British-based Xenova, which licensed its DISC-HSV Vector to Oxxon, EntreMed, which entered an oral formulation of an oncology drug into clinical trials, ID Biomedical, which completed an efficacy/ safety trial of its nasal flu vaccine, and deCODE Genetics, which completed an investigational new drug application for a drug aimed at peripheral arterial occlusive disease...
